Coactivated platelet-derived growth factor receptor α and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma

Cancer Research

Volumn 70, Issue 18, 2010, Pages 7304-7314

  Dewaele, Barbara ^a   Floris, Giuseppe ^a   Finalet Ferreiro, Julio ^a   Fletcher, Christopher D ^c   Coindre, Jean Michel ^d   Guillou, Louis ^e   Hogendoorn, Pancras C W ^f   Wozniak, Agnieszka ^a   Vanspauwen, Vanessa ^a   Schöffski, Patrick ^a   Marynen, Peter ^a,b   Vandenberghe, Peter ^a   Sciot, Raf ^a   Debiec Rychter, Maria ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d INSTITUT BERGONIÉ   (France)

^e UNIVERSITY OF LAUSANNE   (Switzerland)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN MDM2; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; ENZYME ACTIVATION; EX VIVO STUDY; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; INTIMAL SARCOMA; MALE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SARCOMA; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; COMPARATIVE GENOMIC HYBRIDIZATION; ENZYMOLOGY; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; INTIMA; KARYOTYPING; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; VASCULAR NEOPLASMS;

ADULT; AGED; BENZAMIDES; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; MALE; MIDDLE AGED; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SARCOMA; THIAZOLES; TUNICA INTIMA; VASCULAR NEOPLASMS;

EID: 77956940180     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1543     Document Type: Article

References (51)

1. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008;22:1276-312.
2. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999;79:1283-316.
3. Olson LE, Soriano P. Increased PDGFRα activation disrupts connective tissue development and drives systemic fibrosis. Dev Cell 2009;16:303-13.
4. Ostman A, Heldin CH. PDGF receptors as targets in tumor treatment. Adv Cancer Res 2007;97:247-74.
5. Bovee JV, Hogendoorn PC. Molecular pathology of sarcomas: concepts and clinical implications. Virchows Arch 2010;456:193-9.
6. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-10.
7. Sirvent N, Maire G, Pedeutour F. Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer 2003;37:1-19.
8. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-9.
9. Sjoblom T, Shimizu A, O'Brien KP, et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 2001;61:5778-83.
10. Hermanson M, Funa K, Koopmann J, et al. Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor α receptor expression in human malignant gliomas. Cancer Res 1996;56:164-71.
11. Joensuu H, Puputti M, Sihto H, Tynninen O, Nupponen NN. Amplification of genes encoding KIT, PDGFRα and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme. J Pathol 2005;207:224-31.
12. Smith JS, Wang XY, Qian J, et al. Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features. J Neuropathol Exp Neurol 2000;59:495-503.
13. Arai H, Ueno T, Tangoku A, et al. Detection of amplified oncogenes by genome DNA microarrays in human primary esophageal squamous cell carcinoma: comparison with conventional comparative genomic hybridization analysis. Cancer Genet Cytogenet 2003;146:16-21.
14. Bode-Lesniewska B, Zhao J, Speel EJ, et al. Gains of 12q13-14 and overexpression of mdm2 are frequent findings in intimal sarcomas of the pulmonary artery. Virchows Arch 2001;438:57-65.
15. Bode-Lesniewska B, Komminoth P. Intimal sarcoma. In: Fletcher CD, Unni KK, Mertens F, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone. Lyon: IARC; 2002, p. 223-4.
16. Burke AP, Virmani R. Sarcomas of the great vessels. A clinicopathologic study. Cancer 1993;71:1761-73.
17. Hottenrott G, Mentzel T, Peters A, Schroder A, Katenkamp D. Intravascular ("intimal") epithelioid angiosarcoma: clinicopathological and immunohistochemical analysis of three cases. Virchows Arch 1999;435:473-8.
18. Miracco C, Laurini L, Santopietro R, et al. Intimal-type primary sarcoma of the aorta. Report of a case with evidence of rhabdomyosarcomatous differentiation. Virchows Arch 1999;435:62-6.
19. Nishikawa H, Miyakoshi S, Nishimura S, Seki A, Honda K. A case of aortic intimal sarcoma manifested with acutely occurring hypertension and aortic occlusion. Heart Vessels 1989;5:54-8.
20. Nonomura A, Kurumaya H, Kono N, et al. Primary pulmonary artery sarcoma. Report of two autopsy cases studied by immunohistochemistry and electron microscopy, and review of 110 cases reported in the literature. Acta Pathol Jpn 1988;38:883-96.
21. Thalheimer A, Fein M, Geissinger E, Franke S. Intimal angiosarcoma of the aorta: report of a case and review of the literature. J Vasc Surg 2004;40:548-53.
22. Higgins R, Posner MC, Moosa HH, Staley C, Pataki KI, Mendelow H. Mesenteric infarction secondary to tumor emboli from primary aortic sarcoma. Guidelines for diagnosis and management. Cancer 1991;68:1622-7.
23. Penel N, Taieb S, Ceugnart L, et al. Report of eight recent cases of locally advanced primary pulmonary artery sarcomas: failure of doxorubicin-based chemotherapy. J Thorac Oncol 2008;3:907-11.
24. Tamborini E, Casieri P, Miselli F, et al. Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas. J Pathol 2007;212:227-35.
25. Zhao J, Roth J, Bode-Lesniewska B, Pfaltz M, Heitz PU, Komminoth P. Combined comparative genomic hybridization and genomic microarray for detection of gene amplifications in pulmonary artery intimal sarcomas and adrenocortical tumors. Genes Chromosomes Cancer 2002;34:48-57.
26. Knuutila S, Bjorkqvist AM, Autio K, et al. DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol 1998;152:1107-23.
27. Debiec-Rychter M, Lasota J, Sarlomo-Rikala M, Kordek R, Miettinen M. Chromosomal aberrations in malignant gastrointestinal stromal tumors: correlation with c-KIT gene mutation. Cancer Genet Cytogenet 2001;128:24-30.
28. Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001;20:5054-8.
29. Smeets MF, Mooren EH, Abdel-Wahab AH, Bartelink H, Begg AC. Differential repair of radiation-induced DNA damage in cells of human squamous cell carcinoma and the effect of caffeine and cysteamine on induction and repair of DNA double-strand breaks. Radiat Res 1994;140:153-60.
30. Debiec-Rychter M, Wasag B, Stul M, et al. Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity. J Pathol 2004;202:430-8.
31. Dewaele B, Wasag B, Cools J, et al. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin Cancer Res 2008;14:5749-58.
32. Qu Z, Han X, Cui Y, Li C. A PI3 kinase inhibitor found to activate bestrophin 3. J Cardiovasc Pharmacol 2010;55:110-5.
33. Kubo T, Piperdi S, Rosenblum J, et al. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer 2008;112:2119-29.
34. Tamborini E, Virdis E, Negri T, et al. Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordoma. Neuro-oncol 2010;12:776-89.
35. Guillou L, Aurias A. Soft tissue sarcomas with complex genomic profiles. Virchows Arch 2010;456:201-17.
36. Coindre JM, Pedeutour F, Aurias A. Well-differentiated and dedifferentiated liposarcomas. Virchows Arch 2010;456:167-79.
37. Shangary S, Wang S. Small-molecule inhibitors of the MDM2-53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 2009;49:223-41.
38. Tovar C, Rosinski J, Filipovic Z, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A 2006;103:1888-93.
39. Lurje G, Lenz HJ. EGFR signaling and drug discovery. Oncology 2009;77:400-10.
40. Mitsudomi T, Yatabe Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J 2010;277:301-8.
41. Sato O, Wada T, Kawai A, et al. Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases. Cancer 2005;103:1881-90.
42. Stewart CF, Leggas M, Schuetz JD, et al. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res 2004;64:7491-9.
43. Messerschmitt PJ, Rettew AN, Brookover RE, Garcia RM, Getty PJ, Greenfield EM. Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro. Clin Orthop 2008;466:2168-75.
44. Stommel JM, Kimmelman AC, Ying H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007;318:287-90.
45. Yokoi K, Thaker PH, Yazici S, et al. Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model. Cancer Res 2005;65:3716-25.
46. Zhou Y, Li S, Hu YP, et al. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. Cancer Res 2006;66:404-11.
47. Chen Z, Lee FY, Bhalla KN, Wu J. Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Mol Pharmacol 2006;69:1527-33.
48. Li J, Rix U, Fang B, et al. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol 2010;6:291-9.
49. Sato K, Nagao T, Iwasaki T, Nishihira Y, Fukami Y. Src-dependent phosphorylation of the EGF receptor Tyr-845 mediates Stat-p21waf1 pathway in A431 cells. Genes Cells 2003;8:995-1003.
50. Yoshida T, Okamoto I, Okamoto W, et al. Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification. Cancer Sci 2010;101:167-72.
51. Paterson AL, Pole JC, Blood KA, et al. Co-amplification of 8p12 and 11q13 in breast cancers is not the result of a single genomic event. Genes Chromosomes Cancer 2007;46:427-39.